The Journal of Clinical Research Best Practices is a forum for sharing material of practical use in clinical research, and a refuge for material that is too controversial, time-sensitive or non-traditional for other publications. Subscriptions are currently free, and will remain free through 2006 to charter subscribers who subscribe now.

Articles in Current Issue:

(Mis)communicating Cox-2 Clinical Trial Risks
Did Pharma Drop the Ball at FDA Cox-2 Hearings?

Stranger than Fiction: SOP Scandal Strikes Clinical Research Industry
Who would have thought SOPs could ever be this controversial?

Something for Everyone: Standard Operating Procedure Products for the Investigative Site
SOPs are essential for consistent, high-quality research. Here are seven commercial products that can help you create your own.

What Am I Missing Here? Thought-Provoking Questions for the Clinical Research Industry #3
Was this column too hot for the ACRP to handle? Judge for yourself.

It's Time To Go Out: 'Successful Outsourcing of Pharmaceutical R&D' (Review)
Highlights from a $3,750 industry report.

Coming Next Month:

The Study from Hell
A true story from the crypt.

How Safe Is Safe Enough?  Insurance for Investigative Sites
Everything you want to know about insurance, and some things you did not want to know.

What Am I Missing Here? Thought-Provoking Questions for the Clinical Research Industry #4
More ideas that are so crazy they might just make sense.

_______________________________________________
Norman M. Goldfarb
Managing Partner, First Clinical Research
Chairman, MAGI, the Model Agreement Group Initiative
xxxxxx@firstclinical.com http://www.firstclinical.com/
T 650.465.0119 - F 509.471.2815
"Clinical Research Best Practices Consulting"

======================================================================
 Instructions on how to use the RESADM-L Mailing List, including
 subscription information and a web-searchable archive, are available
 via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================